Wixela Inhub (fluticasone propionate and salmeterol inhalation powder), the first substitutable generic of Advair Diskus (GlaxoSmithKline), has been made available by Mylan for the treatment of asthma in patients aged 4 years not adequately controlled on long-term asthma medications or whose disease warrants initiation of treatment with both inhaled corticosteroids and long-acting beta agonists; maintenance treatment of COPD; and the reduction of COPD exacerbations in patients with a history of exacerbations.
Mylan’s therapeutically equivalent generic will be offered at a wholesale acquisition cost that is 70% less than the brand product. Wixela Inhub is available in 3 strengths: 100mcg/50mcg, 250mcg/50mcg and 500mcg/50mcg strengths at a list price of $93.71, $116.44 and $153.14, respectively.
Commenting on the launch, Mylan’s Chief Commercial Officer Tony Mauro said, “We trust that by launching Wixela Inhub at a significantly discounted list price, we will demonstrate the savings that generics can deliver for patients through reduced out-of-pocket costs, as well as the U.S. healthcare system overall.” Mylan will also provide education and training to patients prescribed Wixela Inhub.
Wixela Inhub combines fluticasone propionate, a synthetic corticosteroid, and salmeterol, a long-acting beta2-adrenergic agonist (LABA). The efficacy of Wixela Inhub was found to be equivalent to Advair Diskus in a 28-day, randomized, double-blind, placebo-controlled, parallel group study involving 1128 adult asthma patients.
For more information visit Mylan.com.